Belgian probiotics player Vésale Pharma has made its first steps into the Chinese market with inking a distribution deal in pharma channels.
Vésale Pharma earned a patent for a high-dose microencapsulation probiotic delivery method in 2011, and now it is being to flex its muscles outside its home markets like Belgium and Germany while simultaneously demonstrating growing medical fraternity interest in probiotics.
The new deal links it with a Shenzhen Stock Exchange-listed Chinese firm specialising in paediatric drugs, Hainan Honz Pharmaceutical.
The Chinese deal will see Hainan Honz distribute Vésale’s products nationally.
“Our distribution agreement with Vésale Pharma draws on the strengths of both our companies, creating a strong, strategic partnership for the development, registration, distribution, and sales of Vésale’s probiotic portfolio,” said Hainan Honz’s marketing director, Bin Xiao.
Hainan Honz said it as the first time it had worked with an international firm in the field of probiotics.
“It is a further recognition of Vésale Pharma’s leading position in delivering probiotic solutions for all life stage,” said Vésaleinternational director, Johan Quintens.
In the Middle East, Vésale has won authorisations in the United Arabs Emirates Kuwait with others set to follow.
Its Intelicaps technology uses a ‘smallsphere’ microencapsulation technique that employs molecules of between 0.6 and 1 micro metres, dimensions approaching nano levels.